GlucoTrack, Inc. (GCTK) vs China SXT Pharmaceuticals, Inc. (SXTC)

A side-by-side comparison of GlucoTrack, Inc. and China SXT Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

GCTK

GlucoTrack, Inc.

$901902

$1.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SXTC

China SXT Pharmaceuticals, Inc.

$667469

$1.25HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — GCTK vs SXTC

growth of $100 · dividends reinvested · last 8y

GCTK -100.0% (-75.6%/yr)SXTC -100.0% (-90.0%/yr)GCTK compounded faster over this window

Log scale — wide-divergence pair

GCTK SXTC

Metrics side by side

Total return (annualized)

Metric	GCTK	SXTC
Total return (1Y)	-98.99%	N/A
Total return CAGR (3Y)	-96.29%	N/A
Total return CAGR (5Y)	-92.60%	N/A
Total return CAGR (10Y)	-77.25%	N/A

SXTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full GCTK analysis Full SXTC analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.